At present, one recombinant adenovirus vector vaccine and four inactivated vaccine projects have been successively approved by the state food and drug administration to carry out clinical trials, and no major adverse reactions have been reported so far.If all goes well, phase ii trials will be completed in July.
According to zeng yixin, a recombinant adenovirus vector vaccine and four inactivated vaccines are currently undergoing phase I and phase ii clinical trials in China.So far, a total of 2,575 volunteers have been vaccinated in phase I and phase ii clinical trials.
As of May 13, a total of 2,575 volunteers had been vaccinated in the five vaccination programs, it said.A total of 539 volunteers have been vaccinated in phase I clinical trials, and some have obtained preliminary data on safety and protective antibody production.The phase ii clinical trial has inoculated a total of 2036 volunteers, and is in the process of completing all second or third shots, as well as monitoring and evaluating their safety and efficacy.
Zeng said vaccine research and development in other technical routes is also progressing smoothly and orderly.“It is expected that another project will be approved to enter the clinical trial stage by the state food and drug administration from June.”Since the outbreak of covid-19, the joint prevention and control mechanism of the state council has established a research team led by the ministry of science and technology.The scientific research team set up a special vaccine class, which was responsible for organizing, coordinating and serving various units to promote vaccine research and development.So far, things are going well.
Previously, it was reported that as of May 11, 110 covid-19 vaccines under development had been registered on the who website, of which eight have entered clinical trials.Among them, the adenovirus vector vaccine of the academy of military sciences and the academy of military medicine has carried out phase ii clinical trials.Sinopharm group China biological wuhan institute of biological products and Beijing kexingzhong biological products technology co., ltd. jointly developed the inactivated vaccine with the relevant scientific research institutions, and obtained the combined clinical trial license of phase I and phase ii.The new coronavirus inactivated vaccine developed by the Beijing institute of biological products of China was approved for clinical trial by the state food and drug administration, and the clinical trial was also launched.
In response to
Expanding the scope of nucleic acid testing in wuhan is an important guarantee for the prevention and control of the epidemic
The city of wuhan, hubei province, will carry out nucleic acid tests on its citizens in an orderly manner to determine the number of asymptomatic infections.Zeng yixin, deputy director of the national health commission, said the move is an important guarantee for the prevention and control of covid-19 on a regular basis.
Zeng said the main purpose of the move is to further clarify the scope of the epidemic.Expanding the scope of testing is an important measure to implement the “four early detection” measures, and also an important guarantee for coordinating the resumption of work, production and school, and the prevention and control of the epidemic on a regular basis.
He said that on the basis of a comprehensive scientific assessment of the risk and detection capacity of the epidemic, expanding the scope of nucleic acid testing will not only be conducive to accurate prevention and control, protect people’s health, but also contribute to the rational flow of people and promote the full restoration of social, economic and living order.
To clarify
“Deny who access to the wuhan laboratory” is not true
China attaches great importance to its cooperation with the world health organization (who), li mingzhu, inspector general of the international cooperation department of the national health commission (NHC), said at a press conference of the who on Monday.
Mingzhu said that on January 20, 2011, China hosted a who team to visit wuhan, hubei province. The team visited medical and health institutions, including laboratories, and had in-depth exchanges with experts in hubei.February 16 to 24, received China – the world health organization expert group, to Beijing, sichuan, guangdong and hubei wuhan, comprehensive and in-depth research epidemic situation, prevention and control measures, medical treatment, scientific research, etc., they also to China and all countries in the world epidemic prevention and control are very valuable and constructive Suggestions are put forward.
“Who has never made a request to visit a particular laboratory, so it is not true to say that the who is denied access to the wuhan laboratory.”Li said that since the outbreak of the epidemic, China has been sharing information about the epidemic with the who and the international community in an open, transparent and responsible manner.